Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

2.

Drug delivery in a tumour cord model: a computational simulation.

Hubbard ME, Jove M, Loadman PM, Phillips RM, Twelves CJ, Smye SW.

R Soc Open Sci. 2017 May 24;4(5):170014. doi: 10.1098/rsos.170014. eCollection 2017 May.

3.

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.

Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW.

Clin Cancer Res. 2016 Oct 1;22(19):4776-4785. Epub 2016 May 25.

4.

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.

Braunstein M, Liao L, Lyttle N, Lobo N, Taylor KJ, Krzyzanowski PM, Kalatskaya I, Yao CQ, Stein LD, Boutros PC, Twelves CJ, Marcellus R, Bartlett JM, Spears M.

Breast Cancer Res. 2016 Feb 6;18(1):16. doi: 10.1186/s13058-016-0676-6.

5.

Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling.

Gregory WM, Twelves CJ, Bell R, Smye SW, Howard DR, Coleman RE, Cameron DA.

Breast Cancer Res Treat. 2016 Jan;155(2):303-11. doi: 10.1007/s10549-016-3684-4. Epub 2016 Jan 19.

6.

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI.

J Clin Oncol. 2015 May 20;33(15):1680-7. doi: 10.1200/JCO.2013.54.7869. Epub 2015 Apr 20.

PMID:
25897160
7.

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ.

Ann Oncol. 2015 Apr;26(4):715-24. doi: 10.1093/annonc/mdv003. Epub 2015 Jan 16.

8.

Mathematical and computational models of drug transport in tumours.

Groh CM, Hubbard ME, Jones PF, Loadman PM, Periasamy N, Sleeman BD, Smye SW, Twelves CJ, Phillips RM.

J R Soc Interface. 2014 Mar 12;11(94):20131173. doi: 10.1098/rsif.2013.1173. Print 2014 May 6.

9.

'Being there' for women with metastatic breast cancer: a pan-European patient survey.

Harding V, Afshar M, Krell J, Ramaswami R, Twelves CJ, Stebbing J.

Br J Cancer. 2013 Sep 17;109(6):1543-8. doi: 10.1038/bjc.2013.492. Epub 2013 Sep 3.

10.

Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.

McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ.

J Clin Oncol. 2013 Jul 10;31(20):2600-6. doi: 10.1200/JCO.2013.49.6638. Epub 2013 Jun 3.

11.

Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

Munro AF, Bartels A, Balslev E, Twelves CJ, Cameron DA, Brünner N, Bartlett JM.

Breast Cancer Res. 2013 Apr 9;15(2):R31. doi: 10.1186/bcr3411.

12.

A qualitative investigation of the motivations, experiences and views of female sunbed users under the age of 18 in England.

Lake JR, Thomson CS, Twelves CJ, Davies EA.

J Public Health (Oxf). 2014 Mar;36(1):56-64. doi: 10.1093/pubmed/fds107. Epub 2013 Jan 30.

PMID:
23365261
13.

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.

Earl HM, Hiller L, Dunn JA, Vallier AL, Bowden SJ, Jordan SD, Blows F, Munro A, Bathers S, Grieve R, Spooner DA, Agrawal R, Fernando I, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, McAdam K, Foster L, Leonard RC, Twelves CJ, Cameron D, Bartlett JM, Pharoah P, Provenzano E, Caldas C, Poole CJ; NEAT Investigators and the SCTBG.

Br J Cancer. 2012 Oct 9;107(8):1257-67. doi: 10.1038/bjc.2012.370. Epub 2012 Sep 11.

14.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.

15.

Designing phase II trials in cancer: a systematic review and guidance.

Brown SR, Gregory WM, Twelves CJ, Buyse M, Collinson F, Parmar M, Seymour MT, Brown JM.

Br J Cancer. 2011 Jul 12;105(2):194-9. doi: 10.1038/bjc.2011.235. Epub 2011 Jun 28. Review.

16.

In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.

Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J, Bartlett JM.

Breast Cancer Res Treat. 2012 Apr;132(2):463-70. doi: 10.1007/s10549-011-1606-z. Epub 2011 Jun 3.

PMID:
21638049
17.

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD.

Clin Cancer Res. 2011 Jul 1;17(13):4214-24. doi: 10.1158/1078-0432.CCR-10-2848. Epub 2011 May 16.

18.

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, Laffranchi B, Pellizzoni C, Kroemer G, Armand JP, Balheda R, Twelves CJ.

Cell Cycle. 2011 Mar 15;10(6):963-70. Epub 2011 Mar 15.

PMID:
21368575
19.

Sunbed use in children aged 11-17 in England: face to face quota sampling surveys in the National Prevalence Study and Six Cities Study.

Thomson CS, Woolnough S, Wickenden M, Hiom S, Twelves CJ.

BMJ. 2010 Mar 18;340:c877. doi: 10.1136/bmj.c877.

20.

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ.

Lancet Oncol. 2010 Mar;11(3):266-74. doi: 10.1016/S1470-2045(10)70006-1. Epub 2010 Jan 13.

21.

A mathematical model of doxorubicin penetration through multicellular layers.

Evans CJ, Phillips RM, Jones PF, Loadman PM, Sleeman BD, Twelves CJ, Smye SW.

J Theor Biol. 2009 Apr 21;257(4):598-608. doi: 10.1016/j.jtbi.2008.11.031. Epub 2009 Jan 4. Erratum in: J Theor Biol. 2011 Mar 21;273(1):235.

PMID:
19183560
22.

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.

Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.

J Clin Oncol. 2008 Nov 1;26(31):5027-35. doi: 10.1200/JCO.2007.14.6597. Epub 2008 Sep 2.

PMID:
18768436
23.

Defining the optimal schedule of drug administration: art or science?

Twelves CJ.

J Clin Oncol. 2008 Apr 10;26(11):1781-2. doi: 10.1200/JCO.2007.14.7769. No abstract available.

PMID:
18398142
24.

Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.

Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, Wong A, Lalani AS, Twelves CJ.

Clin Cancer Res. 2008 Feb 15;14(4):1096-104. doi: 10.1158/1078-0432.CCR-07-4020.

25.

Targeting the protein kinase C family: are we there yet?

Mackay HJ, Twelves CJ.

Nat Rev Cancer. 2007 Jul;7(7):554-62. Review. Erratum in: Nat Rev Cancer. 2008 Mar;8(3):nrc2350.

PMID:
17585335
26.
27.

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ; NEAT Investigators and the SCTBG.

N Engl J Med. 2006 Nov 2;355(18):1851-62.

28.

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

Puri R, Palit V, Loadman PM, Flannigan M, Shah T, Choudry GA, Basu S, Double JA, Lenaz G, Chawla S, Beer M, Van Kalken C, de Boer R, Beijnen JH, Twelves CJ, Phillips RM.

J Urol. 2006 Oct;176(4 Pt 1):1344-8.

PMID:
16952628
29.

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

Twelves CJ, Butts CA, Cassidy J, Conroy T, Braud Fd, Diaz-Rubio E, Tabernero JM, Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ.

Clin Colorectal Cancer. 2005 Jul;5(2):101-7.

PMID:
16098250
30.

Quality of life in women with advanced breast cancer treated with docetaxel.

Twelves CJ, Miles DW, Hall A.

Clin Breast Cancer. 2004 Aug;5(3):216-22; discussion 223-4.

PMID:
15335454
31.

Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment.

Thomson CS, Brewster DH, Dewar JA, Twelves CJ; Scottish Cancer Therapy Network.

Eur J Cancer. 2004 Mar;40(5):743-53.

PMID:
15010076
32.

Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status.

Thomson CS, Twelves CJ, Mallon EA, Leake RE; Scottish Cancer Trials Breast Group; Scottish Cancer Therapy Network.

Breast. 2002 Oct;11(5):419-29.

PMID:
14965706
33.

Follow-up in women with breast cancer: the patients' perspective.

Renton JP, Twelves CJ, Yuille FA.

Breast. 2002 Jun;11(3):257-61.

PMID:
14965677
34.

Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer.

Glasspool RM, Twelves CJ.

Breast. 2001 Oct;10(5):368-78.

PMID:
14965609
35.

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.

Johnston SR, Gumbrell LA, Evans TR, Coleman RE, Smith IE, Twelves CJ, Soukop M, Rea DW, Earl HM, Howell A, Jones A, Canney P, Powles TJ, Haynes BP, Nutley B, Grimshaw R, Jarman M, Halbert GW, Brampton M, Haviland J, Dowsett M, Coombes RC; Cancer Research UK Phase I/II Committee.

Cancer Chemother Pharmacol. 2004 Apr;53(4):341-8. Epub 2004 Jan 13.

PMID:
14722733
36.

Protein kinase C: a target for anticancer drugs?

Mackay HJ, Twelves CJ.

Endocr Relat Cancer. 2003 Sep;10(3):389-96. Review.

PMID:
14503915
37.

Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.

Dobbs NA, Twelves CJ, Gregory W, Cruickshanka C, Richards MA, Rubens RD.

Eur J Cancer. 2003 Mar;39(5):580-6.

PMID:
12628836
38.

Oral cancer treatment: developments in chemotherapy and beyond.

O'Neill VJ, Twelves CJ.

Br J Cancer. 2002 Oct 21;87(9):933-7. Review.

39.

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

Vasey PA, Roché H, Bisset D, Terret C, Vernillet L, Riva A, Ramazeilles C, Azli N, Kaye SB, Twelves CJ.

Br J Cancer. 2002 Nov 4;87(10):1072-8.

40.
41.

DNA: still a target worth aiming at? A review of new DNA-interactive agents.

Anthoney DA, Twelves CJ.

Am J Pharmacogenomics. 2001;1(1):67-81. Review.

PMID:
12173316
42.

Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).

Jones RJ, Twelves CJ.

Expert Rev Anticancer Ther. 2002 Feb;2(1):13-22. Review.

PMID:
12113062
43.
44.

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.

Simpson AB, Calvert PM, Sludden JA, Boddy AV, Griffin MJ, Schätzlein A, Wilson P, Fishwick K, Wheatley A, Ross GA, Calvert AH, Twelves CJ.

Ann Oncol. 2002 Mar;13(3):399-402.

PMID:
11996470
45.

Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.

Sharma RA, Eatock MM, Twelves CJ, Brown G, McLelland HR, Clayton KT, O'Byrne KJ, Moyses C, Carmichael J, Steward WP.

Cancer Chemother Pharmacol. 2001 Sep;48(3):197-201.

PMID:
11592340
46.

Variation in survival of women with breast cancer: Health Board remains a factor at 10 years.

Twelves CJ, Thomson CS, Dewar JA, Brewster DH; Scottish Cancer Therapy Network.

Br J Cancer. 2001 Sep 1;85(5):637-40.

47.

Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival.

Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ; Scottish Cancer Therapy Network.

J Epidemiol Community Health. 2001 May;55(5):308-15.

48.

The oral fluorinated pyrimidines.

de Bono JS, Twelves CJ.

Invest New Drugs. 2001;19(1):41-59. Review.

PMID:
11291832
49.

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee.

Twelves CJ, Gardner C, Flavin A, Sludden J, Dennis I, de Bono J, Beale P, Vasey P, Hutchison C, Macham MA, Rodriguez A, Judson I, Bleehen NM.

Br J Cancer. 1999 Aug;80(11):1786-91.

50.

Supplemental Content

Loading ...
Support Center